{"id":38207,"date":"2021-07-21T17:33:00","date_gmt":"2021-07-21T10:33:00","guid":{"rendered":"https:\/\/www.xinwengao.com\/cn\/pr\/2021072117330038207"},"modified":"2021-07-21T21:39:27","modified_gmt":"2021-07-21T13:39:27","slug":"%e7%ac%ac12%e9%a1%b9%ef%bc%81%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%affda%e5%ad%a4%e5%84%bf%e8%8d%af%e8%ae%a4%e5%ae%9a%e5%86%8d%e5%88%9b%e6%96%b0%e9%ab%98%ef%bc%8cmdm2-p53%e6%8a%91%e5%88%b6%e5%89%82apg-115","status":"publish","type":"post","link":"https:\/\/www.xinwengao.com\/cn\/pr\/2021072117330038207","title":{"rendered":"\u7b2c12\u9879\uff01\u4e9a\u76db\u533b\u836fFDA\u5b64\u513f\u836f\u8ba4\u5b9a\u518d\u521b\u65b0\u9ad8\uff0cMDM2-p53\u6291\u5236\u5242APG-115\u83b7ODD\u6cbb\u7597IIB-IV\u671f\u9ed1\u8272\u7d20\u7624"},"content":{"rendered":"<table border=\"0\" cellspacing=\"10\" cellpadding=\"5\" align=\"right\">\n<tbody>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/1419966\/logo_Logo.jpg?p=medium600\" border=\"0\" alt=\"\" title=\"logo\" hspace=\"0\" vspace=\"0\" width=\"118\" \/><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><p>\u4e2d\u56fd\u82cf\u5dde\u548c\u7f8e\u56fd\u9a6c\u91cc\u5170\u5dde\u7f57\u514b\u7ef4\u5c14\u5e022021\u5e747\u670821\u65e5 \/\u7f8e\u901a\u793e\/ &#8212; \u81f4\u529b\u4e8e\u5728\u80bf\u7624\u3001\u4e59\u809d\u53ca\u4e0e\u8870\u8001\u76f8\u5173\u75be\u75c5\u7b49\u6cbb\u7597\u9886\u57df\u5f00\u53d1\u521b\u65b0\u836f\u7269\u7684\u9886\u5148\u7684\u751f\u7269\u533b\u836f\u4f01\u4e1a &#8212; \u4e9a\u76db\u533b\u836f\uff086855.HK\uff09\u4eca\u65e5\u5ba3\u5e03\uff0c\u7f8e\u56fd\u98df\u54c1\u548c\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40\uff08FDA\uff09\u65e5\u524d\u6388\u4e88\u516c\u53f8\u7ec6\u80de\u51cb\u4ea1\u7ba1\u7ebf\u5728\u7814\u539f\u521b\u65b0\u836fMDM2-p53\u6291\u5236\u5242APG-115\u5b64\u513f\u836f\u8d44\u683c\u8ba4\u5b9a\uff08ODD\uff09\uff0c\u7528\u4e8e\u6cbb\u7597IIB-IV\u671f\u9ed1\u8272\u7d20\u7624\u3002\u8fd9\u662fAPG-115\u7ee7\u80c3\u764c\u3001\u6025\u6027\u9ad3\u7cfb\u767d\u8840\u75c5\u3001\u8f6f\u7ec4\u7ec7\u8089\u7624\u3001\u89c6\u7f51\u819c\u6bcd\u7ec6\u80de\u7624\u540e\uff0c\u83b7\u5f97\u7684\u7b2c\u4e94\u9879FDA\u6388\u4e88\u7684\u5b64\u513f\u836f\u8d44\u683c\u8ba4\u5b9a\u3002\u622a\u81f3\u76ee\u524d\uff0c\u4e9a\u76db\u533b\u836f\u5171\u67094\u4e2a\u5728\u7814\u65b0\u836f\u83b7\u5f9712\u9879FDA\u5b64\u513f\u836f\u8ba4\u5b9a\uff0c\u7ee7\u7eed\u5237\u65b0\u4e2d\u56fd\u836f\u4f01\u7684\u8bb0\u5f55\u3002<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder9233\">\n<\/p><\/div>\n<p>\u201c\u5b64\u513f\u836f\u201d\u53c8\u79f0\u4e3a\u7f55\u89c1\u836f\uff0c\u6307\u7528\u4e8e\u9884\u9632\u3001\u6cbb\u7597\u3001\u8bca\u65ad\u7f55\u89c1\u75c5\u7684\u836f\u54c1\u3002\u5728\u7f8e\u56fd\uff0c\u7f55\u89c1\u75be\u75c5\u662f\u6307\u60a3\u75c5\u4eba\u6570\u5c11\u4e8e20\u4e07\u4eba\u7684\u75be\u75c5\u3002\u81ea1983\u5e74\u4ee5\u6765\uff0c\u7f8e\u56fd\u901a\u8fc7\u300a\u5b64\u513f\u836f\u6cd5\u6848\u300b\u7684\u5b9e\u65bd\uff0c\u7ed9\u4e88\u4f01\u4e1a\u76f8\u5173\u653f\u7b56\u6276\u6301\uff0c\u4ee5\u9f13\u52b1\u7f55\u89c1\u75c5\u836f\u54c1\u7684\u7814\u53d1\u3002\u672c\u6b21APG-115\u83b7\u5f97\u7f8e\u56fdFDA\u6388\u4e88\u7684\u5b64\u513f\u836f\u8d44\u683c\u8ba4\u5b9a\uff0c\u5c06\u6709\u52a9\u4e8e\u8be5\u836f\u7269\u5728\u7f8e\u56fd\u7684\u540e\u7eed\u7814\u53d1\u53ca\u5546\u4e1a\u5316\u5f00\u5c55\u7b49\u65b9\u9762\u4eab\u53d7\u4e00\u5b9a\u7684\u653f\u7b56\u652f\u6301\uff0c\u5305\u62ec\u4eab\u6709\u4e34\u5e8a\u8bd5\u9a8c\u8d39\u7528\u7a0e\u6536\u51cf\u514d\u3001\u514d\u9664NDA\u7533\u8bf7\u8d39\u7528\u3001\u83b7\u5f97\u7814\u53d1\u8d44\u52a9\u7b49\uff0c\u7279\u522b\u662f\u6279\u51c6\u4e0a\u5e02\u540e\u53ef\u83b7\u5f97\u7f8e\u56fd\u5e02\u573a7\u5e74\u72ec\u5360\u6743\u3002<\/p>\n<p>\u9ed1\u8272\u7d20\u7624\u662f\u4e00\u79cd\u6f5c\u5728\u81f4\u547d\u7684\u76ae\u80a4\u6076\u6027\u80bf\u7624\uff0c\u5728\u5168\u4e16\u754c\u7684\u53d1\u75c5\u7387\u6301\u7eed\u4e0a\u5347\u3002\u5728\u7f8e\u56fd\uff0c\u76ee\u524d\u60a3\u9ed1\u8272\u7d20\u7624\u7684\u7ec8\u751f\u98ce\u9669\u4e3a1\/63<sup>[1]<\/sup>\u3002\u6570\u636e\u663e\u793a2019\u5e74\u7f8e\u56fd\u65b0\u589e\u9ed1\u8272\u7d20\u7624\u60a3\u8005\u7ea696,480\u540d\uff0c\u56e0\u9ed1\u8272\u7d20\u7624\u6b7b\u4ea1\u7684\u60a3\u8005\u7ea67,230\u540d<sup>[2]<\/sup>\u3002\u9ed1\u8272\u7d20\u7624\u7684\u9884\u540e\u53d6\u51b3\u4e8e\u8bca\u65ad\u65f6\u7684\u5206\u671f\u3002\u7f8e\u56fdSEER\uff08Surveillance, Epidemiology, and End Results\uff09\u6570\u636e\u5e93\u5bf92011\u5e74\u81f32015\u5e74\u7684\u9ed1\u8272\u7d20\u7624\u75c5\u4f8b\u8fdb\u884c\u56de\u987e\u6027\u5206\u6790\u540e\u53d1\u73b0\uff0c\u7ea6\u670975%\u7684\u60a3\u8005\u5728\u8bca\u65ad\u65f6\u4e3aI\u671f\uff0c15%\u7684\u60a3\u8005\u4e3aII\u671f\uff0c7.5%\u4e3aIII\u671f\uff0c2.5%\u4e3aIV\u671f<sup>[3]<\/sup>\u3002<\/p>\n<p>\u81ea2011\u5e74\u4ee5\u6765\uff0c\u9ed1\u8272\u7d20\u7624\u7684\u4e34\u5e8a\u6cbb\u7597\u53d6\u5f97\u4e86\u524d\u6240\u672a\u6709\u7684\u8fdb\u5c55\u3002\u9776\u5411\u7597\u6cd5\u548c\u514d\u75ab\u7597\u6cd5\u7b49\u65b0\u6cbb\u7597\u65b9\u5f0f\u7684\u51fa\u73b0\uff0c\u6781\u5927\u7684\u5ef6\u957f\u4e86\u60a3\u8005\u751f\u5b58\u5468\u671f\u5e76\u6539\u5584\u4e86\u60a3\u8005\u751f\u5b58\u8d28\u91cf<sup>[4-6]<\/sup>\u3002\u514d\u75ab\u7597\u6cd5\u4e2d\uff0c\u4ee5\u6297CTLA-4\u5355\u6297\u3001\u6297PD-1\u5355\u6297\u548c\u6297PD-L1\u5355\u6297\u4e3a\u4ee3\u8868\u7684\u514d\u75ab\u68c0\u67e5\u70b9\u6291\u5236\u5242\uff08ICI, immune checkpoint inhibitor\uff09\u7684\u4e34\u5e8a\u7814\u7a76\u6700\u6210\u719f\u3001\u5e94\u7528\u6700\u5e7f\u6cdb\u3002\u5c3d\u7ba1\u5982\u6b64\uff0c\u76f8\u5f53\u6570\u91cf\u7684\u60a3\u8005\u6700\u7ec8\u4f1a\u51fa\u73b0ICI\u8010\u836f\uff0c\u800c\u8fc4\u4eca\u4ecd\u6ca1\u6709\u4efb\u4f55\u6cbb\u7597\u65b9\u5f0f\u83b7\u6279\u7528\u4e8e\u6cbb\u7597ICI\u8010\u836f\u7684\u9ed1\u8272\u7d20\u7624\u60a3\u8005\u3002<\/p>\n<p>APG-115\u662f\u4e9a\u76db\u533b\u836f\u5728\u7814\u7684\u4e00\u79cd\u53e3\u670d\u3001\u9ad8\u9009\u62e9\u6027\u7684MDM2-p53\u6291\u5236\u5242\u3002\u4e34\u5e8a\u524d\u7814\u7a76\u53d1\u73b0\uff0c\u5176\u4e0ePD-1\u6291\u5236\u5242\u8054\u5408\u4f7f\u7528\u65f6\uff0c\u53ef\u4ee5\u89e6\u53d1\u9002\u5e94\u6027\u6297\u80bf\u7624\u514d\u75ab\u4ee5\u589e\u5f3a\u6297\u80bf\u7624\u6d3b\u6027\u3002\u5728\u4eca\u5e74\u7684\u7f8e\u56fd\u4e34\u5e8a\u80bf\u7624\u5b66\u4f1a\uff08ASCO\uff09\u5e74\u4f1a\u4e0a\uff0c\u4e9a\u76db\u533b\u836f\u53e3\u5934\u62a5\u544a\u4e86APG-115\u8054\u5408\u5e15\u535a\u5229\u73e0\u5355\u6297\u7684II\u671f\u4e34\u5e8a\u7814\u7a76\u6700\u65b0\u8fdb\u5c55\u3002\u6570\u636e\u663e\u793a\u4e86\u826f\u597d\u7684\u6297\u80bf\u7624\u6d3b\u6027\u548c\u5b89\u5168\u6027\uff0c\u5728APG-115\u8054\u5408\u5e15\u535a\u5229\u73e0\u5355\u6297\u6cbb\u7597PD-1 \/ PD-L1\u6291\u5236\u5242\u8010\u836f\u7684\u9ed1\u8272\u7d20\u7624\u961f\u5217\u4e2d\uff0c\u6709\u4e00\u4f8b\u60a3\u8005\u83b7\u5f97\u5b8c\u5168\u7f13\u89e3\uff08CR\uff09\uff0c\u8be5\u961f\u5217\u7684\u5ba2\u89c2\u7f13\u89e3\u7387\uff08ORR\uff09\u8fbe24.1%\uff0c\u75be\u75c5\u63a7\u5236\u7387\uff08DCR\uff09\u8fbe&nbsp;55.2%\u3002\u8fd9\u4e00\u6570\u636e\u4e3aAPG-115\u548c\u514d\u75ab\u80bf\u7624\u836f\u7269\u7684\u534f\u540c\u4f5c\u7528\u63d0\u4f9b\u4e86\u4e34\u5e8a\u9a8c\u8bc1\uff0c\u4e5f\u4e3aICI\u8010\u836f\u7684\u9ed1\u8272\u7d20\u7624\u60a3\u8005\u5e26\u6765\u4e86\u65b0\u7684\u6cbb\u7597\u5e0c\u671b\u3002<\/p>\n<p>\u4e9a\u76db\u533b\u836f\u9996\u5e2d\u533b\u5b66\u5b98\u7fdf\u4e00\u5e06\u535a\u58eb\u8868\u793a\uff1a\u201c\u9488\u5bf9\u9ed1\u8272\u7d20\u7624\u7684\u6cbb\u7597\u76ee\u524d\u4ecd\u5b58\u5728\u8f83\u5927\u7684\u3001\u5c1a\u672a\u6ee1\u8db3\u7684\u4e34\u5e8a\u9700\u6c42\uff0c\u56e0\u6b64\uff0cAPG-115\u83b7\u5f97\u6b64\u9879\u5b64\u513f\u836f\u8ba4\u5b9a\u610f\u4e49\u975e\u51e1\u3002\u6b64\u6b21APG-115\u65a9\u83b7\u7684\u7b2c\u4e94\u9879\u5b64\u513f\u836f\u8ba4\u5b9a\u548c\u4e9a\u76db\u533b\u836f\u65a9\u83b7\u7684\u7b2c12\u9879\u5b64\u513f\u836f\u8ba4\u5b9a\uff0c\u8fdb\u4e00\u6b65\u5792\u5b9e\u4e86\u6211\u4eec\u2018\u521b\u4e2d\u56fd\u836f\u4f01\u5b64\u513f\u836f\u8ba4\u8bc1\u5386\u6765\u4e4b\u6700\u2019\u7684\u9886\u5148\u5730\u4f4d\uff0c\u4e5f\u4f53\u73b0\u4e86\u516c\u53f8\u5168\u7403\u5316\u521b\u65b0\u80fd\u529b\u4e0e\u6c34\u5e73\u3002\u672a\u6765\u6211\u4eec\u5c06\u7ee7\u7eed\u575a\u5b88<span id=\"spanHghlt7e07\">\u2018<\/span>\u89e3\u51b3\u4e2d\u56fd\u4e43\u81f3\u5168\u7403\u60a3\u8005\u5c1a\u672a\u6ee1\u8db3\u7684\u4e34\u5e8a\u9700\u6c42<span id=\"spanHghlt2603\">\u2019<\/span>\u7684\u4f7f\u547d\u3002\u5e0c\u671b\u5728FDA\u5b64\u513f\u836f\u653f\u7b56\u7684\u63a8\u52a8\u4e0b\uff0c\u5305\u62ecAPG-115\u5728\u5185\u7684\u591a\u4e2a\u516c\u53f8\u5728\u7814\u54c1\u79cd\u80fd\u8fdb\u4e00\u6b65\u52a0\u5feb\u4e34\u5e8a\u5f00\u53d1\uff0c\u65e9\u65e5\u83b7\u6279\uff0c\u4ece\u800c\u66f4\u5feb\u7684\u9020\u798f\u66f4\u591a\u60a3\u8005\u3002\u201d<\/p>\n<p><b>\u53c2\u8003\u6587\u732e<\/b><\/p>\n[1]. Stephanie C, Christy S, Jessica W. Epidemiology and Risk Factors of Melanoma. <span class=\"xn-person\">Surg Clin North Am.<\/span> 2020 Feb;100(1):1-12.<br \/>[2]. Cancer Facts &amp; Figures 2019. American Cancer Society. Link: <a target=\"_blank\" href=\"https:\/\/www.cancer.org\/research\/cancer-facts-statistics\/all-cancer-facts-figures\/cancer-facts-figures-2019.html\" rel=\"nofollow noopener\">https:\/\/www.cancer.org\/research\/cancer-facts-statistics\/all-cancer-facts-figures\/cancer-facts-figures-2019.html<\/a><br \/>[3]. Andrew P, Jason L. Considering adjuvant therapy for stage II melanoma. Cancer. 2020 Mar 15;126(6):1166-1174.<br \/>[4]. GV Long, Victoria A, Jonathan C, et al. Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase <span class=\"xn-money\">1b<\/span> trial. Lancet Oncol. 2017 Sep;18(9):1202-1210.<br \/>[5]. Jacob S, Antoni R, Georgina L, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). The Lancet. 2017 Oct 21;390(10105):1853-1862.<br \/>[6]. Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 2017 <span class=\"xn-chron\">Oct 5<\/span>;377(14):1345-1356.<\/p>\n<p><b>\u5173\u4e8e\u4e9a\u76db\u533b\u836f<\/b><\/p>\n<p>\u4e9a\u76db\u533b\u836f\u662f\u4e00\u5bb6\u7acb\u8db3\u4e2d\u56fd\u3001\u9762\u5411\u5168\u7403\u7684\u5904\u4e8e\u4e34\u5e8a\u5f00\u53d1\u9636\u6bb5\u7684\u539f\u521b\u65b0\u836f\u7814\u53d1\u4f01\u4e1a\uff0c\u81f4\u529b\u4e8e\u5728\u80bf\u7624\u3001\u4e59\u809d\u53ca\u4e0e\u8870\u8001\u76f8\u5173\u7684\u75be\u75c5\u7b49\u6cbb\u7597\u9886\u57df\u5f00\u53d1\u521b\u65b0\u836f\u7269\u30022019\u5e7410\u670828\u65e5\uff0c\u4e9a\u76db\u533b\u836f\u5728\u9999\u6e2f\u8054\u4ea4\u6240\u4e3b\u677f\u6302\u724c\u4e0a\u5e02\uff0c\u80a1\u7968\u4ee3\u7801\uff1a6855.HK\u3002<\/p>\n<p>\u4e9a\u76db\u533b\u836f\u62e5\u6709\u81ea\u4e3b\u6784\u5efa\u7684\u86cb\u767d-\u86cb\u767d\u76f8\u4e92\u4f5c\u7528\u9776\u5411\u836f\u7269\u8bbe\u8ba1\u5e73\u53f0\uff0c\u5904\u4e8e\u7ec6\u80de\u51cb\u4ea1\u901a\u8def\u65b0\u836f\u7814\u53d1\u7684\u5168\u7403\u6700\u524d\u6cbf\u3002\u516c\u53f8\u5df2\u5efa\u7acb\u62e5\u67098\u4e2a\u5df2\u8fdb\u5165\u4e34\u5e8a\u5f00\u53d1\u9636\u6bb5\u76841\u7c7b\u5c0f\u5206\u5b50\u65b0\u836f\u4ea7\u54c1\u7ba1\u7ebf\uff0c\u5305\u62ec\u6291\u5236Bcl-2\u3001IAP \u6216&nbsp;MDM2-p53 \u7b49\u7ec6\u80de\u51cb\u4ea1\u8def\u5f84\u5173\u952e\u86cb\u767d\u7684\u6291\u5236\u5242\uff1b\u65b0\u4e00\u4ee3\u9488\u5bf9\u764c\u75c7\u6cbb\u7597\u4e2d\u51fa\u73b0\u7684\u6fc0\u9176\u7a81\u53d8\u4f53\u7684\u6291\u5236\u5242\u7b49\uff0c\u4e3a\u5168\u7403\u552f\u4e00\u5728\u7ec6\u80de\u51cb\u4ea1\u8def\u5f84\u5173\u952e\u86cb\u767d\u9886\u57df\u5747\u6709\u4e34\u5e8a\u5f00\u53d1\u54c1\u79cd\u7684\u521b\u65b0\u516c\u53f8\u3002\u76ee\u524d\u516c\u53f8\u6b63\u5728\u4e2d\u56fd\u3001\u7f8e\u56fd\u3001\u6fb3\u5927\u5229\u4e9a\u53ca\u6b27\u6d32\u5f00\u5c5540\u591a\u9879I\/II\u671f\u4e34\u5e8a\u8bd5\u9a8c\u3002\u516c\u53f8\u5148\u540e\u627f\u62c5\u591a\u9879\u56fd\u5bb6\u79d1\u6280\u91cd\u5927\u4e13\u9879\uff0c\u5176\u4e2d\u201c\u91cd\u5927\u65b0\u836f\u521b\u5236\u201d\u4e13\u98795\u9879\uff0c\u5305\u62ec1\u9879\u201c\u4f01\u4e1a\u521b\u65b0\u836f\u7269\u5b75\u5316\u57fa\u5730\u201d\u53ca4\u9879\u201c\u521b\u65b0\u836f\u7269\u7814\u53d1\u201d\uff0c\u53e6\u5916\u627f\u62c5\u201c\u91cd\u5927\u4f20\u67d3\u75c5\u9632\u6cbb\u201d\u4e13\u98791\u9879\u3002\u7528\u4e8e\u6cbb\u7597\u8010\u836f\u6027\u6162\u6027\u9ad3\u6027\u767d\u8840\u75c5\u7684\u6838\u5fc3\u54c1\u79cdHQP1351\u5df2\u5728\u4e2d\u56fd\u9012\u4ea4\u65b0\u836f\u4e0a\u5e02\u7533\u8bf7\uff0c\u5e76\u83b7\u7eb3\u5165\u4f18\u5148\u5ba1\u8bc4\u548c\u7a81\u7834\u6027\u6cbb\u7597\u54c1\u79cd\u3002\u8be5\u54c1\u79cd\u8fd8\u83b7\u5f97\u4e86\u7f8e\u56fdFDA\u5ba1\u8bc4\u5feb\u901f\u901a\u9053\u53ca\u5b64\u513f\u836f\u8ba4\u8bc1\u8d44\u683c\u3002\u622a\u81f3\u76ee\u524d\uff0c\u516c\u53f8\u5171\u67094\u4e2a\u5728\u7814\u65b0\u836f\u83b7\u5f9712\u9879FDA\u5b64\u513f\u836f\u8d44\u683c\u8ba4\u8bc1\u3002<\/p>\n<p>\u51ed\u501f\u5f3a\u5927\u7684\u7814\u53d1\u80fd\u529b\uff0c\u4e9a\u76db\u533b\u836f\u5df2\u5728\u5168\u7403\u8303\u56f4\u5185\u8fdb\u884c\u77e5\u8bc6\u4ea7\u6743\u5e03\u5c40\uff0c\u5e76\u4e0eUNITY\u3001MD Anderson\u3001\u6885\u5965\u533b\u5b66\u4e2d\u5fc3\u548cDana-Farber\u764c\u75c7\u7814\u7a76\u6240\u3001\u9ed8\u6c99\u4e1c\u3001\u963f\u65af\u5229\u5eb7\u7b49\u9886\u5148\u7684\u751f\u7269\u6280\u672f\u53ca\u533b\u836f\u516c\u53f8\u3001\u5b66\u672f\u673a\u6784\u8fbe\u6210\u5168\u7403\u5408\u4f5c\u5173\u7cfb\u3002\u516c\u53f8\u5df2\u5efa\u7acb\u4e00\u652f\u5177\u6709\u4e30\u5bcc\u7684\u539f\u521b\u65b0\u836f\u7814\u53d1\u4e0e\u4e34\u5e8a\u5f00\u53d1\u7ecf\u9a8c\u7684\u56fd\u9645\u5316\u4eba\u624d\u56e2\u961f\uff0c\u540c\u65f6\uff0c\u516c\u53f8\u6b63\u5728\u9ad8\u6807\u51c6\u6253\u9020\u540e\u671f\u7684\u5546\u4e1a\u5316\u751f\u4ea7\u53ca\u5e02\u573a\u8425\u9500\u56e2\u961f\u3002\u4e9a\u76db\u533b\u836f\u5c06\u4e0d\u65ad\u63d0\u9ad8\u7814\u53d1\u80fd\u529b\uff0c\u52a0\u901f\u63a8\u8fdb\u516c\u53f8\u4ea7\u54c1\u7ba1\u7ebf\u7684\u4e34\u5e8a\u5f00\u53d1\u8fdb\u5ea6\uff0c\u771f\u6b63\u8df5\u884c\u201c\u89e3\u51b3\u4e2d\u56fd\u4e43\u81f3\u5168\u7403\u60a3\u8005\u5c1a\u672a\u6ee1\u8db3\u7684\u4e34\u5e8a\u9700\u6c42\u201d\u7684\u4f7f\u547d\uff0c\u4ee5\u9020\u798f\u66f4\u591a\u60a3\u8005\u3002<\/p>\n<p><b>\u524d\u77bb\u6027\u58f0\u660e<\/b><\/p>\n<p>\u672c\u6587\u6240\u4f5c\u51fa\u7684\u524d\u77bb\u6027\u9648\u8ff0\u4ec5\u4e0e\u672c\u6587\u4f5c\u51fa\u8be5\u9648\u8ff0\u5f53\u65e5\u7684\u4e8b\u4ef6\u6216\u8d44\u6599\u6709\u5173\u3002\u9664\u6cd5\u5f8b\u89c4\u5b9a\u5916\uff0c\u4e8e\u4f5c\u51fa\u524d\u77bb\u6027\u9648\u8ff0\u5f53\u65e5\u4e4b\u540e\uff0c\u65e0\u8bba\u662f\u5426\u51fa\u73b0\u65b0\u8d44\u6599\u3001\u672a\u6765\u4e8b\u4ef6\u6216\u5176\u4ed6\u60c5\u51b5\uff0c\u6211\u4eec\u5e76\u65e0\u8d23\u4efb\u66f4\u65b0\u6216\u516c\u5f00\u4fee\u6539\u4efb\u4f55\u524d\u77bb\u6027\u9648\u8ff0\u53ca\u9884\u6599\u4e4b\u5916\u7684\u4e8b\u4ef6\u3002\u8bf7\u7ec6\u9605\u672c\u6587\uff0c\u5e76\u7406\u89e3\u6211\u4eec\u7684\u5b9e\u9645\u672a\u6765\u4e1a\u7ee9\u6216\u8868\u73b0\u53ef\u80fd\u4e0e\u9884\u671f\u6709\u91cd\u5927\u5dee\u5f02\u3002\u672c\u6587\u5185\u6240\u6709\u9648\u8ff0\u4e43\u672c\u6587\u7ae0\u520a\u53d1\u65e5\u671f\u4f5c\u51fa\uff0c\u53ef\u80fd\u56e0\u672a\u6765\u53d1\u5c55\u800c\u51fa\u73b0\u53d8\u52a8\u3002<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder0\">  <\/div>\n<p>\u76f8\u5173\u94fe\u63a5 :<\/p>\n<blockquote class=\"wp-embedded-content\" data-secret=\"oRUBU32xJt\"><p><a href=\"https:\/\/www.ascentagepharma.com\/\">A Leader in the Discovery and Development of Small Molecules that Disrupt Protein-Protein Interactions<\/a><\/p><\/blockquote>\n<p><iframe class=\"wp-embedded-content\" sandbox=\"allow-scripts\" security=\"restricted\" style=\"position: absolute; clip: rect(1px, 1px, 1px, 1px);\" title=\"&#8220;A Leader in the Discovery and Development of Small Molecules that Disrupt Protein-Protein Interactions&#8221; &#8212; Ascentage Pharma\" src=\"https:\/\/www.ascentagepharma.com\/embed\/#?secret=oRUBU32xJt\" data-secret=\"oRUBU32xJt\" width=\"600\" height=\"338\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\"><\/iframe><\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u4e2d\u56fd\u82cf\u5dde\u548c\u7f8e\u56fd\u9a6c\u91cc\u5170\u5dde\u7f57\u514b\u7ef4\u5c14\u5e022021\u5e747\u670821\u65e5 \/\u7f8e\u901a\u793e\/ &#8212; \u81f4\u529b\u4e8e\u5728\u80bf\u7624\u3001\u4e59\u809d\u53ca\u4e0e\u8870\u8001\u76f8\u5173\u75be\u75c5\u7b49\u6cbb\u7597\u9886\u57df\u5f00\u53d1\u521b\u65b0\u836f\u7269\u7684\u9886\u5148\u7684\u751f\u7269\u533b\u836f\u4f01\u4e1a &#8212; \u4e9a\u76db\u533b\u836f\uff086855.HK\uff09\u4eca\u65e5\u5ba3\u5e03\uff0c\u7f8e\u56fd\u98df\u54c1\u548c\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40\uff08FDA\uff09\u65e5\u524d\u6388\u4e88\u516c\u53f8\u7ec6\u80de\u51cb\u4ea1\u7ba1\u7ebf\u5728\u7814\u539f\u521b\u65b0\u836fMDM2-p53\u6291\u5236\u5242APG-115\u5b64\u513f\u836f\u8d44\u683c\u8ba4\u5b9a\uff08ODD\uff09\uff0c\u7528\u4e8e\u6cbb\u7597IIB-IV\u671f\u9ed1\u8272\u7d20\u7624\u3002\u8fd9\u662fAPG-115\u7ee7\u80c3\u764c\u3001\u6025\u6027\u9ad3\u7cfb\u767d\u8840\u75c5\u3001\u8f6f\u7ec4\u7ec7\u8089\u7624\u3001\u89c6\u7f51\u819c\u6bcd\u7ec6\u80de\u7624\u540e\uff0c\u83b7\u5f97\u7684\u7b2c\u4e94\u9879FDA\u6388\u4e88\u7684\u5b64\u513f\u836f\u8d44\u683c\u8ba4\u5b9a\u3002\u622a\u81f3\u76ee\u524d\uff0c\u4e9a\u76db\u533b\u836f\u5171\u67094\u4e2a\u5728\u7814\u65b0\u836f\u83b7\u5f9712\u9879FDA\u5b64\u513f\u836f\u8ba4\u5b9a\uff0c\u7ee7\u7eed\u5237\u65b0\u4e2d\u56fd\u836f\u4f01\u7684\u8bb0\u5f55\u3002 \u201c\u5b64\u513f\u836f\u201d\u53c8\u79f0\u4e3a\u7f55\u89c1\u836f\uff0c\u6307\u7528\u4e8e\u9884\u9632\u3001\u6cbb\u7597\u3001\u8bca\u65ad\u7f55\u89c1\u75c5\u7684\u836f\u54c1\u3002\u5728\u7f8e\u56fd\uff0c\u7f55\u89c1\u75be\u75c5\u662f\u6307\u60a3\u75c5\u4eba\u6570\u5c11\u4e8e20\u4e07\u4eba\u7684\u75be\u75c5\u3002\u81ea1983\u5e74\u4ee5\u6765\uff0c\u7f8e\u56fd\u901a\u8fc7\u300a\u5b64\u513f\u836f\u6cd5\u6848\u300b\u7684\u5b9e\u65bd\uff0c\u7ed9\u4e88\u4f01\u4e1a\u76f8\u5173\u653f\u7b56\u6276\u6301\uff0c\u4ee5\u9f13\u52b1\u7f55\u89c1\u75c5\u836f\u54c1\u7684\u7814\u53d1\u3002\u672c\u6b21APG-115\u83b7\u5f97\u7f8e\u56fdFDA\u6388\u4e88\u7684\u5b64\u513f\u836f\u8d44\u683c\u8ba4\u5b9a\uff0c\u5c06\u6709\u52a9\u4e8e\u8be5\u836f\u7269\u5728\u7f8e\u56fd\u7684\u540e\u7eed\u7814\u53d1\u53ca\u5546\u4e1a\u5316\u5f00\u5c55\u7b49\u65b9\u9762\u4eab\u53d7\u4e00\u5b9a\u7684\u653f\u7b56\u652f\u6301\uff0c\u5305\u62ec\u4eab\u6709\u4e34\u5e8a\u8bd5\u9a8c\u8d39\u7528\u7a0e\u6536\u51cf\u514d\u3001\u514d\u9664NDA\u7533\u8bf7\u8d39\u7528\u3001\u83b7\u5f97\u7814\u53d1\u8d44\u52a9\u7b49\uff0c\u7279\u522b\u662f\u6279\u51c6\u4e0a\u5e02\u540e\u53ef\u83b7\u5f97\u7f8e\u56fd\u5e02\u573a7\u5e74\u72ec\u5360\u6743\u3002 \u9ed1\u8272\u7d20\u7624\u662f\u4e00\u79cd\u6f5c\u5728\u81f4\u547d\u7684\u76ae\u80a4\u6076\u6027\u80bf\u7624\uff0c\u5728\u5168\u4e16\u754c\u7684\u53d1\u75c5\u7387\u6301\u7eed\u4e0a\u5347\u3002\u5728\u7f8e\u56fd\uff0c\u76ee\u524d\u60a3\u9ed1\u8272\u7d20\u7624\u7684\u7ec8\u751f\u98ce\u9669\u4e3a1\/63[1]\u3002\u6570\u636e\u663e\u793a2019\u5e74\u7f8e\u56fd\u65b0\u589e\u9ed1\u8272\u7d20\u7624\u60a3\u8005\u7ea696,480\u540d\uff0c\u56e0\u9ed1\u8272\u7d20\u7624\u6b7b\u4ea1\u7684\u60a3\u8005\u7ea67,230\u540d[2]\u3002\u9ed1\u8272\u7d20\u7624\u7684\u9884\u540e\u53d6\u51b3\u4e8e\u8bca\u65ad\u65f6\u7684\u5206\u671f\u3002\u7f8e\u56fdSEER\uff08Surveillance, Epidemiology, and End Results\uff09\u6570\u636e\u5e93\u5bf92011\u5e74\u81f32015\u5e74\u7684\u9ed1\u8272\u7d20\u7624\u75c5\u4f8b\u8fdb\u884c\u56de\u987e\u6027\u5206\u6790\u540e\u53d1\u73b0\uff0c\u7ea6\u670975%\u7684\u60a3\u8005\u5728\u8bca\u65ad\u65f6\u4e3aI\u671f\uff0c15%\u7684\u60a3\u8005\u4e3aII\u671f\uff0c7.5%\u4e3aIII\u671f\uff0c2.5%\u4e3aIV\u671f[3]\u3002 \u81ea2011\u5e74\u4ee5\u6765\uff0c\u9ed1\u8272\u7d20\u7624\u7684\u4e34\u5e8a\u6cbb\u7597\u53d6\u5f97\u4e86\u524d\u6240\u672a\u6709\u7684\u8fdb\u5c55\u3002\u9776\u5411\u7597\u6cd5\u548c\u514d\u75ab\u7597\u6cd5\u7b49\u65b0\u6cbb\u7597\u65b9\u5f0f\u7684\u51fa\u73b0\uff0c\u6781\u5927\u7684\u5ef6\u957f\u4e86\u60a3\u8005\u751f\u5b58\u5468\u671f\u5e76\u6539\u5584\u4e86\u60a3\u8005\u751f\u5b58\u8d28\u91cf[4-6]\u3002\u514d\u75ab\u7597\u6cd5\u4e2d\uff0c\u4ee5\u6297CTLA-4\u5355\u6297\u3001\u6297PD-1\u5355\u6297\u548c\u6297PD-L1\u5355\u6297\u4e3a\u4ee3\u8868\u7684\u514d\u75ab\u68c0\u67e5\u70b9\u6291\u5236\u5242\uff08ICI, immune checkpoint inhibitor\uff09\u7684\u4e34\u5e8a\u7814\u7a76\u6700\u6210\u719f\u3001\u5e94\u7528\u6700\u5e7f\u6cdb\u3002\u5c3d\u7ba1\u5982\u6b64\uff0c\u76f8\u5f53\u6570\u91cf\u7684\u60a3\u8005\u6700\u7ec8\u4f1a\u51fa\u73b0ICI\u8010\u836f\uff0c\u800c\u8fc4\u4eca\u4ecd\u6ca1\u6709\u4efb\u4f55\u6cbb\u7597\u65b9\u5f0f\u83b7\u6279\u7528\u4e8e\u6cbb\u7597ICI\u8010\u836f\u7684\u9ed1\u8272\u7d20\u7624\u60a3\u8005\u3002 APG-115\u662f\u4e9a\u76db\u533b\u836f\u5728\u7814\u7684\u4e00\u79cd\u53e3\u670d\u3001\u9ad8\u9009\u62e9\u6027\u7684MDM2-p53\u6291\u5236\u5242\u3002\u4e34\u5e8a\u524d\u7814\u7a76\u53d1\u73b0\uff0c\u5176\u4e0ePD-1\u6291\u5236\u5242\u8054\u5408\u4f7f\u7528\u65f6\uff0c\u53ef\u4ee5\u89e6\u53d1\u9002\u5e94\u6027\u6297\u80bf\u7624\u514d\u75ab\u4ee5\u589e\u5f3a\u6297\u80bf\u7624\u6d3b\u6027\u3002\u5728\u4eca\u5e74\u7684\u7f8e\u56fd\u4e34\u5e8a\u80bf\u7624\u5b66\u4f1a\uff08ASCO\uff09\u5e74\u4f1a\u4e0a\uff0c\u4e9a\u76db\u533b\u836f\u53e3\u5934\u62a5\u544a\u4e86APG-115\u8054\u5408\u5e15\u535a\u5229\u73e0\u5355\u6297\u7684II\u671f\u4e34\u5e8a\u7814\u7a76\u6700\u65b0\u8fdb\u5c55\u3002\u6570\u636e\u663e\u793a\u4e86\u826f\u597d\u7684\u6297\u80bf\u7624\u6d3b\u6027\u548c\u5b89\u5168\u6027\uff0c\u5728APG-115\u8054\u5408\u5e15\u535a\u5229\u73e0\u5355\u6297\u6cbb\u7597PD-1 \/ PD-L1\u6291\u5236\u5242\u8010\u836f\u7684\u9ed1\u8272\u7d20\u7624\u961f\u5217\u4e2d\uff0c\u6709\u4e00\u4f8b\u60a3\u8005\u83b7\u5f97\u5b8c\u5168\u7f13\u89e3\uff08CR\uff09\uff0c\u8be5\u961f\u5217\u7684\u5ba2\u89c2\u7f13\u89e3\u7387\uff08ORR\uff09\u8fbe24.1%\uff0c\u75be\u75c5\u63a7\u5236\u7387\uff08DCR\uff09\u8fbe&nbsp;55.2%\u3002\u8fd9\u4e00\u6570\u636e\u4e3aAPG-115\u548c\u514d\u75ab\u80bf\u7624\u836f\u7269\u7684\u534f\u540c\u4f5c\u7528\u63d0\u4f9b\u4e86\u4e34\u5e8a\u9a8c\u8bc1\uff0c\u4e5f\u4e3aICI\u8010\u836f\u7684\u9ed1\u8272\u7d20\u7624\u60a3\u8005\u5e26\u6765\u4e86\u65b0\u7684\u6cbb\u7597\u5e0c\u671b\u3002 \u4e9a\u76db\u533b\u836f\u9996\u5e2d\u533b\u5b66\u5b98\u7fdf\u4e00\u5e06\u535a\u58eb\u8868\u793a\uff1a\u201c\u9488\u5bf9\u9ed1\u8272\u7d20\u7624\u7684\u6cbb\u7597\u76ee\u524d\u4ecd\u5b58\u5728\u8f83\u5927\u7684\u3001\u5c1a\u672a\u6ee1\u8db3\u7684\u4e34\u5e8a\u9700\u6c42\uff0c\u56e0\u6b64\uff0cAPG-115\u83b7\u5f97\u6b64\u9879\u5b64\u513f\u836f\u8ba4\u5b9a\u610f\u4e49\u975e\u51e1\u3002\u6b64\u6b21APG-115\u65a9\u83b7\u7684\u7b2c\u4e94\u9879\u5b64\u513f\u836f\u8ba4\u5b9a\u548c\u4e9a\u76db\u533b\u836f\u65a9\u83b7\u7684\u7b2c12\u9879\u5b64\u513f\u836f\u8ba4\u5b9a\uff0c\u8fdb\u4e00\u6b65\u5792\u5b9e\u4e86\u6211\u4eec\u2018\u521b\u4e2d\u56fd\u836f\u4f01\u5b64\u513f\u836f\u8ba4\u8bc1\u5386\u6765\u4e4b\u6700\u2019\u7684\u9886\u5148\u5730\u4f4d\uff0c\u4e5f\u4f53\u73b0\u4e86\u516c\u53f8\u5168\u7403\u5316\u521b\u65b0\u80fd\u529b\u4e0e\u6c34\u5e73\u3002\u672a\u6765\u6211\u4eec\u5c06\u7ee7\u7eed\u575a\u5b88\u2018\u89e3\u51b3\u4e2d\u56fd\u4e43\u81f3\u5168\u7403\u60a3\u8005\u5c1a\u672a\u6ee1\u8db3\u7684\u4e34\u5e8a\u9700\u6c42\u2019\u7684\u4f7f\u547d\u3002\u5e0c\u671b\u5728FDA\u5b64\u513f\u836f\u653f\u7b56\u7684\u63a8\u52a8\u4e0b\uff0c\u5305\u62ecAPG-115\u5728\u5185\u7684\u591a\u4e2a\u516c\u53f8\u5728\u7814\u54c1\u79cd\u80fd\u8fdb\u4e00\u6b65\u52a0\u5feb\u4e34\u5e8a\u5f00\u53d1\uff0c\u65e9\u65e5\u83b7\u6279\uff0c\u4ece\u800c\u66f4\u5feb\u7684\u9020\u798f\u66f4\u591a\u60a3\u8005\u3002\u201d \u53c2\u8003\u6587\u732e [1]. Stephanie C, Christy S, Jessica W. Epidemiology and Risk Factors of Melanoma. Surg Clin North Am. 2020 Feb;100(1):1-12.[2]. Cancer Facts &amp; Figures 2019. American Cancer Society. Link: https:\/\/www.cancer.org\/research\/cancer-facts-statistics\/all-cancer-facts-figures\/cancer-facts-figures-2019.html[3]. Andrew P, Jason L. Considering&hellip; <a class=\"read-more\" href=\"https:\/\/www.xinwengao.com\/cn\/pr\/2021072117330038207\">Read More<\/a><\/p>\n","protected":false},"author":556,"featured_media":8278,"comment_status":"close","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1965],"tags":[],"class_list":["post-38207","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-partnerships"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts\/38207","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/users\/556"}],"replies":[{"embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/comments?post=38207"}],"version-history":[{"count":1,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts\/38207\/revisions"}],"predecessor-version":[{"id":38208,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts\/38207\/revisions\/38208"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/media\/8278"}],"wp:attachment":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/media?parent=38207"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/categories?post=38207"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/tags?post=38207"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}